These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 26004980)

  • 1. Treatment adherence in schizophrenia: a patient-level meta-analysis of combined CATIE and EUFEST studies.
    Czobor P; Van Dorn RA; Citrome L; Kahn RS; Fleischhacker WW; Volavka J
    Eur Neuropsychopharmacol; 2015 Aug; 25(8):1158-66. PubMed ID: 26004980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hostility in schizophrenia: An integrated analysis of the combined Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and the European First Episode Schizophrenia Trial (EUFEST) studies.
    Volavka J; Van Dorn RA; Citrome L; Kahn RS; Fleischhacker WW; Czobor P
    Eur Psychiatry; 2016 Jan; 31():13-9. PubMed ID: 26657597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insight and medication adherence in schizophrenia: An analysis of the CATIE trial.
    Kim J; Ozzoude M; Nakajima S; Shah P; Caravaggio F; Iwata Y; De Luca V; Graff-Guerrero A; Gerretsen P
    Neuropharmacology; 2020 May; 168():107634. PubMed ID: 31077729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment adherence and insight in schizophrenia.
    Bitter I; Fehér L; Tényi T; Czobor P
    Psychiatr Hung; 2015; 30(1):18-26. PubMed ID: 25867885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians.
    Naber D; Lambert M
    CNS Drugs; 2009 Aug; 23(8):649-59. PubMed ID: 19594194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Therapeutic alliance, a stake in schizophrenia].
    Charpentier A; Goudemand M; Thomas P
    Encephale; 2009 Feb; 35(1):80-9. PubMed ID: 19250998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST).
    Gaebel W; Riesbeck M; von Wilmsdorff M; Burns T; Derks EM; Kahn RS; Rössler W; Fleischhacker WW;
    Eur Neuropsychopharmacol; 2010 May; 20(5):310-6. PubMed ID: 20202800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Predictors of medication non-adherence among a Moroccan sample of patients with schizophrenia: A cross sectional study].
    El Ammouri A; Kisra H
    Encephale; 2017 Dec; 43(6):522-527. PubMed ID: 27663045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What do large scale studies of medication in schizophrenia add to our management strategies?
    Agius M; Davis A; Gilhooley M; Chapman S; Zaman R
    Psychiatr Danub; 2010 Jun; 22(2):323-8. PubMed ID: 20562774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic subgroups for remission, response, and treatment continuation in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) trial.
    Jakubovski E; Carlson JP; Bloch MH
    J Clin Psychiatry; 2015 Nov; 76(11):1535-45. PubMed ID: 26581028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adherence to antipsychotic drug treatment in early-episode schizophrenia: a six-month naturalistic follow-up study.
    Baloush-Kleinman V; Levine SZ; Roe D; Shnitt D; Weizman A; Poyurovsky M
    Schizophr Res; 2011 Aug; 130(1-3):176-81. PubMed ID: 21636254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with poor satisfaction with treatment and trial discontinuation in chronic schizophrenia.
    Schoemaker JH; Vingerhoets AJJM; Emsley RA
    CNS Spectr; 2019 Aug; 24(4):380-389. PubMed ID: 29866212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of discontinuation of antipsychotic medication and subsequent outcomes in the European First Episode Schizophrenia Trial (EUFEST).
    Landolt K; Rössler W; Ajdacic-Gross V; Derks EM; Libiger J; Kahn RS; Fleischhacker WW;
    Schizophr Res; 2016 Apr; 172(1-3):145-51. PubMed ID: 26922655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attitudes toward antipsychotic medications as a useful feature in exploring medication non-adherence in schizophrenia.
    Samalin L; de Chazeron I; Blanc O; Brunel L; Fond G; Llorca PM
    Schizophr Res; 2016 Dec; 178(1-3):1-5. PubMed ID: 27637362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Attributable risk of co-morbid substance use disorder in poor observance to pharmacological treatment and the occurrence of relapse in schizophrenia].
    Ameller A; Gorwood P
    Encephale; 2015 Apr; 41(2):174-83. PubMed ID: 25838239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The NIMH-CATIE Schizophrenia Study: what did we learn?
    Lieberman JA; Stroup TS
    Am J Psychiatry; 2011 Aug; 168(8):770-5. PubMed ID: 21813492
    [No Abstract]   [Full Text] [Related]  

  • 18. Factors associated with adherence to treatment with olanzapine and other atypical antipsychotic medications in patients with schizophrenia.
    Liu-Seifert H; Osuntokun OO; Feldman PD
    Compr Psychiatry; 2012 Jan; 53(1):107-15. PubMed ID: 21310400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of patient and clinician perspectives in the assessment of antipsychotic medication adherence.
    Barbui C; Kikkert M; Mazzi MA; Becker T; Bindman J; Schene A; Nosè M; Helm H; Thornicroft G; Tansella M
    Psychopathology; 2009; 42(5):311-7. PubMed ID: 19672133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The stable patient with schizophrenia--from antipsychotic effectiveness to adherence.
    Thomas P
    Eur Neuropsychopharmacol; 2007 Mar; 17 Suppl 2():S115-22. PubMed ID: 17336766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.